Cannabinoid CB1 receptor ligand binding and function examined through mutagenesis studies of F200 and S383

European Journal of Pharmacology

Volumn 651, Issue 1-3, 2011, Pages 9-17

  Sitkoff, Doree F ^a   Lee, Ning ^a   Ellsworth, Bruce A ^a   Huang, Qi ^a,c   Kang, Liya ^a   Baska, Roseann ^a   Huang, Yanting ^a   Sun, Chongqing ^a   Pendri, Annapurna ^a   Malley, Mary F ^a   Scaringe, Raymond P ^a   Gougoutas, Jack Z ^a   Reggio, Patricia H ^b   Ewing, William R ^a   Pelleymounter, Mary Ann ^a   Carlson, Kenneth E ^a,d  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c Anchor Therapeutics Inc ^*  (United States)

^d Anchor Therapeutics   (United States)

Author keywords

Aromatic stacking; Cannabinoid receptor; Constitutive activity; G protein coupled receptor; Mutagenesis; Rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [2 METHYL 5 [(NAPHTHALEN 1 YLOXY)METHYL]PHENYLSULFONYL]MORPHINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; N [1 BENZYL 6 (TRIFLUOROMETHYL) 1,2,3,4 TETRAHYDROQUINOLIN 3 YL]BENZENESULFONAMIDE; QUINOLIN 8 YL 4 METHYL 3 (MORPHOLINOSULFONYL)BENZOATE; RIMONABANT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; LIGAND BINDING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; WILD TYPE;

ANIMALS; BENZOATES; CHO CELLS; CRICETINAE; CRICETULUS; DRUG INVERSE AGONISM; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MUTAGENESIS; PHENYLALANINE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; QUINOLINES; RECEPTOR, CANNABINOID, CB1; SERINE; SULFONAMIDES;

EID: 78650678016     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.056     Document Type: Article

References (23)

1. M.E. Abood Molecular biology of cannabinoid receptors Handbook of Experimental Pharmacology 168 2005 81 115
2. Ballesteros, J.A.a.W., H., 1995. Integrated Methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. In: S.M., C.P.M.a.S. (Ed.), Methods in Neuroscience. Academic Press, San Diego, pp. 366-428.
3. Barth, F., Casellas, P., Congy, C., Martinez, S., Rinaldi, M., Anne-Archard, G., 1997. Pyrazole derivatives as cannanabinoid receptor agonists. Patent No. 5, 624, 941.
4. 1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization Biochemistry 45 2006 5606 5617
5. Q. Hill, and C.K. Skylaris Including dispersion interactions in the ONETEP program for linear-scaling density functional theory calculations Proc. R. Soc. A465 2009 669 683
6. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
7. D.P. Hurst, D.L. Lynch, J. Barnett-Norris, S.M. Hyatt, H.H. Seltzman, M. Zhong, Z.H. Song, J. Nie, D. Lewis, and P.H. Reggio N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor Mol. Pharm. 62 2002 1274 1287
8. 1 transmembrane helix 7 Mol. Pharm. 71 2007 1512 1524
9. 1 cannabinoid receptor transmembrane helix II for signal transduction J. Pharmacol. Exp. Ther. 325 2008 342 348
10. N. Lambeng, F. Lebon, B. Christophe, M. Burton, M. De Ryck, and L. Quere Arylsulfonamides as a new class of cannabinoid CB(1) receptor ligands: identification of a lead and initial SAR studies Bioorg. Med. Chem. Lett. 17 2007 272 277
11. 1 cannabinoid receptor antagonists J. Med. Chem. 48 2005 1823 1838
12. L.S. Lin, S. Ha, R.G. Ball, N.N. Tsou, L.A. Castonguay, G.A. Doss, T.M. Fong, C.P. Shen, J.C. Xiao, M.T. Goulet, and W.K. Hagmann Conformational analysis and receptor docking of N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy} propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist J. Med. Chem. 51 2008 2108 2114
13. S.D. McAllister, G. Rizvi, S. Anavi-Goffer, D.P. Hurst, J. Barnett-Norris, D.L. Lynch, P.H. Reggio, and M.E. Abood An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region J. Med. Chem. 46 2003 5139 5152
14. 1 receptor activation J. Biol. Chem. 279 2004 48024 48037
15. 2 cannabinoid receptors FEBS Lett. 580 2006 5392 5398
16. J.H. Park, P. Scheerer, K.P. Hofmann, H.W. Choe, and O.P. Ernst Crystal structure of the ligand-free G-protein-coupled receptor opsin Nature 454 2008 183 187
17. R.P. Picone, A.D. Khanolkar, W. Xu, L.A. Ayotte, G.A. Thakur, D.P. Hurst, M.E. Abood, P.H. Reggio, D.J. Fournier, and A. Makriyannis (-)-7′- Isothiocyanato-11-hydroxy-1′, 1′-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor Mol. Pharm. 68 2005 1623 1635
18. 1 receptor J. Med. Chem. 47 2004 3048 3057
19. C.P. Shen, J.C. Xiao, H. Armstrong, W. Hagmann, and T.M. Fong F200A substitution in the third transmembrane helix of human cannabinoid CB(1) receptor converts AM2233 from receptor agonist to inverse agonist Eur. J. Pharmacol. 531 2006 41 46
20. J.Y. Shim, W.J. Welsh, E. Cartier, J.L. Edwards, and A.C. Howlett Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor J. Med. Chem. 45 2002 1447 1459
21. C. Sun, D. Sitkoff, Y. Huang, Y. Zhou, Z. Gu, N. Murugesan, L. Kang, Y. Yang, R.A. Baska, M.J. Cullen, M.A. Pelleymounter, P. Stetsko, O. Gudmunsson, O. Flint, S. Johngher, S. Wu, K. Behnia, K. Carlson, and W.R. Ewing Tetrahydroquinolines as novel cannabinoid-1 receptor antagonists 232nd American Chemical Society National Meeting, San Francisco 2006
22. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, and S. Rossner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397 (Pubitemid 40523733)
23. J.L. Wiley, J.J. Burston, D.C. Leggett, O.O. Alekseeva, R.K. Razdan, A. Mahadevan, and B.R. Martin CB(1) cannabinoid receptor-mediated modulation of food intake in mice Br. J. Pharmacol. 145 2005 293 300